Hjem › Multipelt myelom › Illinois › Chicago
Multipelt myelom kliniske forsøg i Chicago, IL
22 studier for Multipelt myelom søger deltagere på steder i og omkring Chicago (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RekruttererFase 1
- University of Chicago Medical Center /ID# 278863, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruttererFase 3
- Research Site, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RekruttererFase 1/2
- University of Chicago Medical Center, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Rush University System for Health, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruttererFase 3
- University Of Illinois Medical Center, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruttererFase 4
- Northwestern University, Chicago
- University of Chicago, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
RekruttererFase 2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
- Cancer Treatment Centers of America-Chicago, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
RekruttererFase 2
- University of Illinois at Chicago, Chicago
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekruttererFase 3
- Endeavor Health - Swedish Hospital, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekruttererFase 3
- Advocate Illinois Masonic Medical Center, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruttererFase 3
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Rekrutterer
- Northwestern University Feinberg School of Medicine, Chicago
Personalized Autologous Transplant for Multiple Myeloma
RekruttererFase 1
- University Illinois Chicago, Chicago
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruttererFase 3
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruttererFase 1
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekruttererFase 1
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
RekruttererFase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
RekruttererFase 1
- University of Illinois Cancer Center, Chicago
Multipelt myelom forsøg i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Seattle, WA22 studier
Andre studier i Chicago
- Ikke-småcellet lungecancer61 studier
- Brystkræft58 studier
- Kræft (alle typer)51 studier
- Metastatisk cancer45 studier
- Prostatakræft45 studier
- Overvægt41 studier
- Lungecancer41 studier
- Ægstockræft36 studier
- Slagtilfælde34 studier
- Colorektal kræft33 studier
- Hjertesvigt31 studier
- Overvægt28 studier
Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.